To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Either etodolac 400mg bid or naproxen 500mg bid effective versus placebo in knee OA treatment

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
September 2017

Either etodolac 400mg bid or naproxen 500mg bid effective versus placebo in knee OA treatment

Vol: 6| Issue: 9| Number:32| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study

Clin Ther. 1995 Jul-Aug;17(4):656-66

Contributing Authors:
R Dore I Ballard G Constantine P McDonald

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

254 patients with symptomatic knee osteoarthritis were randomized to receive either etodolac 400mg, naproxen 500mg, or placebo for 4 weeks. Patients were assessed for clinical efficacy using Patients' and Physicians' Global Assessments, and safety was assessed using the incidence of adverse events. Both etodolac and naproxen demonstrated significantly better results for clinical efficacy compared ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue